MedTrace Logo

Soluble B7-H3 as a Biomarker for Osteosarcoma

NCT05942456 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-05-14

No results posted yet for this study

Summary

Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.

Conditions

Interventions

DIAGNOSTIC_TEST

ELISA: enzyme-linked immunosorbent assay

enzyme-linked immunosorbent assay

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-05
Primary Completion
2024-07-01
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05942456 on ClinicalTrials.gov